ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

分组1 - ImmunityBio reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, but an improvement from a loss of $0.20 per share a year ago, indicating a surprise of -25% [1] - The company posted revenues of $16.52 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.25%, and showing a significant increase from revenues of $0.04 million in the same quarter last year [2] - ImmunityBio shares have declined approximately 19.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] 分组2 - The earnings outlook for ImmunityBio is mixed, with the current consensus EPS estimate for the coming quarter at -$0.12 on revenues of $21.11 million, and -$0.44 on revenues of $93.87 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which ImmunityBio belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]